Objective To investigate the correlation between serum specific immunoglobulin E (SIgE) level and vestibular function in Ménière's disease (MD).Methods From January 2018 to January 2021, 52 patients with Meniere's disease and 30 healthy volunteers who were treated in our hospital during the same period were selected and recorded as the study group and the control group, respectively. Clinical data, serum immune protein E levels [total immunoglobulin E (TIgE), SIgE], auditory vestibular function indexes [vestibular function reduction value, speech frequency, auditory brainstem response (ABR) I to V interval, ocular vestibular evoked myogenic potential (oVEMP), and cervical vestibular evoked myogenic potential (cVEMP) ] were compared. The serum immune protein E levels and auditory vestibular function indexes of MD patients with different clinical stages were compared. The relationship between serum immune protein levels and auditory vestibular function in MD patients was analyzed. A receiver operating curve (ROC) was prepared to evaluate the predictive value of serum immune protein levels on the severity of hearing impairment in MD patients by area under the curve (AUC).Results The serum levels of TIgE and SIgE in the study group were higher than those in the control group (P < 0.05). The vestibular function reduction value, speech frequency, ABR I to V interval time, oVEMP and cVEMP potential values in the study group were higher than those in the control group (P < 0.05). The levels of serum TIgE, SIgE, vestibular function reduction, speech frequency, ABR I to V interval time, oVEMP and cVEMP potential values in stage Ⅳ MD patients were all higher than those in stage I, Ⅱ, and Ⅲ (P < 0.05). The serum levels of TIgE and SIgE, vestibular function reduction, speech frequency, ABR I to V interval time, oVEMP and cVEMP potential values in MD patients were all higher than those in stage I and stage Ⅱ (P < 0.05). The serum TIgE and SIgE levels, vestibular function reduction value, speech frequency, ABR I to V interval time, oVEMP and cVEMP potential values in stage ⅡMD patients were all higher than those in stage I (P < 0.05). Pearson correlation analysis showed that TIgE level was positively correlated with speech frequency in MD patients (r = 0.583, P = 0.007), SIgE level was correlated with vestibular function impairment (r = 0.643, P = 0.000), speech frequency (r = 0.796, P = 0.000), ABR I to V interval time (r = 0.589, P = 0.008), oVEMP (r = 0.538, P = 0.005), and cVEMP potential value (r = 0.608, P = 0.002) were all positively correlated (P < 0.05). The sensitivities of serum TIgE, SIgE, and their combination in predicting the severity of hearing impairment in MD patients were 64.29% (95% CI: 0.441, 0.807), 75.00% (95% CI: 0.548, 0.886), 64.29% (95% CI: 0.441, 0.807), the specificity was 75.00% (95% CI: 0.530, 0.894), 70.83% (95% CI: 0.488, 0.866), and 95.83% (95% CI: 0.769, 0.998), and the AUC was 0.681 (95% CI: 0.537, 0.803), 0.789 (95% CI: 0.653, 0.890), and 0.864 (95% CI: 0.739, 0.947), respectively.Conclusion The serum immune protein levels in MD patients are related to vestibular function in MD patients, and the combination of serum TIgE and SIgE has a higher predictive value for the severity of hearing abnormalities in MD patients.